Brind.

Jazz Pharmaceuticals reported that oncology headwinds offset neuroscience momentum in its portfolio.

2 reports, 2 independent Updated Aug 13
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Jazz Pharmaceuticals reported that oncology headwinds offset neuroscience momentum in its portfolio.

Who's involved

What this event is mainly about
Jazz Pharmaceuticals

How it developed

Newest first. Tap a step to see who reported it.
  1. Jazz Pharma's portfolio saw oncology headwinds offset by neuroscience momentum.1 source
  2. Neuroscience assets drive revenue for Jazz Pharma, but sales decreased due to competition and protocol changes.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • StockStoryJAZZ Q2 Deep Dive: Pipeline Milestones and Oncology Headwinds Shape Outlook Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) met Wall Street’s revenue expectations in Q2 CY2025, with sales up 2.1
  • GuruFocus.comJazz Pharmaceuticals PLC (JAZZ) Q2 2025 Earnings Call Highlights: Strong Neuroscience ... Total Revenue: $1.05 billion in Q2 2025, a 2% increase year-over-year. Xywav Revenue: $415 million, a 13% inc